PT1305334E - Proteínas de urocortina e suas utilizações - Google Patents

Proteínas de urocortina e suas utilizações Download PDF

Info

Publication number
PT1305334E
PT1305334E PT01963759T PT01963759T PT1305334E PT 1305334 E PT1305334 E PT 1305334E PT 01963759 T PT01963759 T PT 01963759T PT 01963759 T PT01963759 T PT 01963759T PT 1305334 E PT1305334 E PT 1305334E
Authority
PT
Portugal
Prior art keywords
ucn
crf
urp
urocortin
human
Prior art date
Application number
PT01963759T
Other languages
English (en)
Inventor
Wylie W Vale
Paul F Sawchenko
Kathy A Lewis
Joan M Vaughan
Teresa M Reyes
Jean E Rivier
John B Hogenesch
Marilyn H Perrin
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of PT1305334E publication Critical patent/PT1305334E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57509Corticotropin releasing factor [CRF] (Urotensin)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
PT01963759T 2000-08-04 2001-07-31 Proteínas de urocortina e suas utilizações PT1305334E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22325500P 2000-08-04 2000-08-04
US27396901P 2001-03-07 2001-03-07

Publications (1)

Publication Number Publication Date
PT1305334E true PT1305334E (pt) 2008-12-30

Family

ID=26917597

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01963759T PT1305334E (pt) 2000-08-04 2001-07-31 Proteínas de urocortina e suas utilizações

Country Status (16)

Country Link
US (4) US6838274B2 (pt)
EP (1) EP1305334B1 (pt)
JP (1) JP4873825B2 (pt)
KR (1) KR100879232B1 (pt)
CN (1) CN1484650B (pt)
AT (1) ATE408622T1 (pt)
AU (2) AU8468301A (pt)
CA (1) CA2418144C (pt)
CY (1) CY1110424T1 (pt)
DE (1) DE60135850D1 (pt)
DK (1) DK1305334T3 (pt)
ES (1) ES2313978T3 (pt)
IL (2) IL154102A0 (pt)
PT (1) PT1305334E (pt)
RU (1) RU2278871C2 (pt)
WO (1) WO2002012307A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2313978T3 (es) * 2000-08-04 2009-03-16 Research Development Foundation Proteinas urocortina y sus usos.
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
AU2002306853B2 (en) 2001-03-15 2006-07-06 Research Development Foundation Urocortin-III and uses thereof
US6936585B2 (en) 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
EP2114437A2 (en) * 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
US9555032B2 (en) * 2007-06-13 2017-01-31 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling
AU2008297908A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
KR20100056515A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
CA2771769C (en) * 2009-08-28 2019-10-29 Research Development Foundation Urocortin 2 analogs and uses thereof
US9314506B2 (en) 2011-10-24 2016-04-19 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
DK2814513T3 (en) * 2012-02-14 2018-02-26 Univ California Systemic administration and regulated expression of paracrine for cardiovascular disease and other conditions
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
CN110826145B (zh) * 2019-09-09 2020-08-28 西安工业大学 基于超启发式马氏链进化的汽车多参数运行工况设计方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223792A1 (en) * 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Urocortin peptides
ES2313978T3 (es) 2000-08-04 2009-03-16 Research Development Foundation Proteinas urocortina y sus usos.
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

Also Published As

Publication number Publication date
AU2001284683B2 (en) 2006-04-27
CA2418144A1 (en) 2002-02-14
EP1305334A4 (en) 2005-03-23
DE60135850D1 (de) 2008-10-30
RU2278871C2 (ru) 2006-06-27
US6838274B2 (en) 2005-01-04
KR20030074589A (ko) 2003-09-19
CN1484650A (zh) 2004-03-24
US20020127221A1 (en) 2002-09-12
US20070191592A1 (en) 2007-08-16
US7223846B2 (en) 2007-05-29
IL154102A0 (en) 2003-07-31
DK1305334T3 (da) 2009-02-02
WO2002012307A1 (en) 2002-02-14
EP1305334A1 (en) 2003-05-02
US8044025B2 (en) 2011-10-25
US7638607B2 (en) 2009-12-29
CY1110424T1 (el) 2015-04-29
ES2313978T3 (es) 2009-03-16
AU8468301A (en) 2002-02-18
CN1484650B (zh) 2012-12-12
EP1305334B1 (en) 2008-09-17
CA2418144C (en) 2013-06-18
IL154102A (en) 2010-12-30
US20050191650A1 (en) 2005-09-01
RU2003105897A (ru) 2005-01-20
JP4873825B2 (ja) 2012-02-08
JP2004505640A (ja) 2004-02-26
ATE408622T1 (de) 2008-10-15
US20100168021A1 (en) 2010-07-01
KR100879232B1 (ko) 2009-01-20

Similar Documents

Publication Publication Date Title
CY1110424T1 (el) Πρωτεϊνες ουροκορτινης και χρησεις αυτων
Zhao et al. The purification and partial amino acid sequence of a polypeptide from the glutelin fraction of rice grains; homology to pea legumin
CA2055963C (en) Chimeric fibroblast growth factor
EP3428182A2 (en) Anti-inflammatory peptides and composition comprising the same
KASAI et al. Determination of the complete amino acid sequence of calmodulin (phenylalanine-rich acidic protein II) from bovine brain
Graham et al. Complete amino acid sequence of soybean leaf P21: similarity to the thaumatin-like polypeptides
CA2438851A1 (en) Interleukin-18 mutants, their production and use
Crabb et al. Characterization of multiple forms of prostatropin (prostate epithelial cell growth factor) from bovine brain
CA2461443A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
Schmelzer et al. Biochemical characterization of recombinant human nerve growth factor
Browning et al. Disulfide scrambling of interleukin-2: HPLC resolution of the three possible isomers
Minchiotti et al. Two alloalbumins with identical electrophoretic mobility are produced by differently charged amino acid substitutions
Gayler et al. Biosynthesis, cDNA and amino acid sequences of a precursor of conglutin δ, a sulphur-rich protein from Lupinus angustifolius
Harper et al. Human class 1 heparin-binding growth factor: structure and homology to bovine acidic brain fibroblast growth factor
Araki et al. The position of the disulfide bonds in human plasma α2HS-glycoprotein and the repeating double disulfide bonds in the domain structure
ATE287952T1 (de) Humanes thymosin beta 15 gen,protein und dessen verwendungen
Leszyk et al. Amino acid sequence of a 15 kilodalton actin-binding fragment of turkey gizzard caldesmon: Similarity with dystrophin, tropomysin and the tropomyosin-binding region of troponin T
Lundwall et al. Chemical characterization of cyanogen bromide fragments from the β‐chain of human complement factor C3
Yoo et al. Identification of the secretory vesicle membrane binding region of chromogranin B
Bharali et al. Amino acid sequence of the 26 kDa subunit of legumin-type seed storage protein of common buckwheat (Fagopyrum esculentum Moench): molecular characterization and phylogenetic analysis
GIUFRIDA et al. The amino-acid sequence of two isoforms of α-lactalbumin from donkey (Equus asinus) milk is identical
Uegaki et al. Characterization of the DNA binding domain of the mouse IRF-2 protein
Boumaiza et al. Expression and purification of a new recombinant camel hepcidin able to promote the degradation of the iron exporter ferroportin1
Shuck et al. Cloning, heterologous expression and characterization of murine interleukin 1 receptor antagonist protein
Lai et al. Two novel Bv8-like peptides from skin secretions of the toad Bombina maxima